by Lisa Nadal | Mar 16, 2023 | Past Events
Prof. Dario Neri (CEO and CSO), and Emanuele Puca (Investor Relations) will participate at the event to present Philogen and its programs to the financial community.by Lisa Nadal | Mar 16, 2023 | Past Events
Dr. Covelli (CMO), Dr. Elia, Dr. Ravenni, and Dr. Nadal will participate at the event in Rome. The dermato-oncology team from St. Gallen will give a presentation entitled “Intralesional administration of L19IL2/L19TNF in difficult-to-treat BCC patients shows favorable...by Lisa Nadal | Nov 11, 2022 | 2022, Past Events, Scientific
The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More detailsby Lisa Nadal | Nov 7, 2022 | 2022, Press Releases, Scientific
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP) positive tumors. The...by Lisa Nadal | Oct 19, 2022 | 2022, Press Releases, Scientific
The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs are currently being developed for the imaging and therapy...